ライフサイエンスコーパス: Rituxan

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 d CD20, the target for antibody therapy with Rituxan.

2 mab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has

3 own to activate complement (e.g., Herceptin, Rituxan, and Erbitux) could be significantly enhanced if

4 ort demonstrating the safety and efficacy of Rituxan anti-CD20 chimeric antibody in combination with

5 ent clinical recovery and is undergoing CHOP-Rituxan chemotherapy.

6 o demonstrate the safety and efficacy of the Rituxan chimeric anti-CD20 antibody in combination with

7 Rituxan did not seem to compromise the ability of patien

8 get the cell surface marker CD20 (rituximab; Rituxan for hematologic malignancies and rheumatoid arth

9 It was found that homodimers of Rituxan had superior antigrowth activity in vitro and th

10 Rituxan has a long half-life and low immunogenicity, and

11 Rituxan homodimers, compared with monomers, also rendere

12 Rituximab (Rituxan, IDEC-C2B8) has been shown to sensitize non-Hodg

13 The chimeric anti-CD20 antibody rituximab (Rituxan, IDEC-C2B8) is widely used in the clinical treat

14 tuximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemothe

15 Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA) is the fir

16 therapy with monoclonal antibody rituximab (Rituxan) in a short period of time and continued to be t

17 Homodimers, but not monomers, of Rituxan induced both apoptosis and necrosis of several B

18 Myc(OFF)CD20(HIGH) cells were more prone to Rituxan-induced apoptosis than Myc(ON)CD20(MED).

19 Rituxan induces apoptosis in some tumor cell lines in vi

20 Rituximab (Rituxan) is a human-mouse chimeric monoclonal antibody t

21 ing anti-CD20 monoclonal antibody rituximab (Rituxan) is underway in type 1 diabetes patients.

22 dex (IPI) score > or = 2, the combination of Rituxan plus CHOP achieved an ORR of 89% and CR of 56%.

23 d the monoclonal antibody to CD20 rituximab (Rituxan) promoted long-term islet allograft survival in

24 ts trastuzumab (Herceptin(R)) and rituximab (Rituxan(R)), engaged both activation (FcgammaRIII) and i

25 ecific CTLs can eradicate both untreated and Rituxan-resistant lymphomatous EBV-LPD, with failures as

26 Rituxan (Rituximab) is a chimeric mAb with human IgG1 co

27 himeric anti-CD20 monoclonal antibody (mAb) (Rituxan) was approved for the treatment of low-grade/fol

28 to other therapeutic antibodies (Avastin and Rituxan) was observed.

29 f IgG or F(ab')(2) homodimers vs monomers of Rituxan were compared for their ability to inhibit the g

30 The most frequent events attributed to Rituxan were fever and chills, observed primarily with t

31 e most frequent adverse events attributed to Rituxan were fever and chills, primarily during the firs

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。